Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

被引:3
|
作者
Gwyther, SJ
Nielsen, OS
Judson, IR
van Glabbeke, M
Verweij, J
机构
[1] E Surrey Hosp, Surrey & Sussex NHS Trust, Surrey RH1 5RH, England
[2] Aarhus Univ Hosp, DK-800 Aarhus C, Denmark
[3] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[4] EORTC Data Ctr, B-1200 Brussels, Belgium
[5] Rotterdam Canc Inst, Daniel den Hoed Klin, NL-3008 AE Rotterdam, Netherlands
[6] Univ Hosp, NL-3008 AE Rotterdam, Netherlands
关键词
claimed responses; independent radiological; review; peer review; response rate;
D O I
10.1097/00001813-200007000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR). Investigators claiming a response submitted the relevant chest radiographs (CXR) or scans to two other members of the STBSG for peer review. The reviewers completed a questionnaire indicating overall response or reasons for rejecting the claimed responses. An independent radiologist also reviewed the cases and he was blinded to the results of the peer review until the study was concluded. Twenty-two patients were reviewed by the radiologist and peer review, and the completed questionnaires were retrospectively reviewed. Two differences were noted, one partial responder (PR) was regarded as stable disease by the radiologist and one PR by peer review was determined a complete response by the radiologist. The radiologist found subsequent evidence of progressive disease in three patients who initially showed a PR, whilst the review group noted only one. This study suggests peer review in this tumor type is a satisfactory method of achieving an accurate, objective RR. [(C) 2000 Lippincott Williams & Wilkins].
引用
收藏
页码:433 / 437
页数:5
相关论文
共 50 条
  • [41] Phase II trial of ifosfamide in combination with sorafenib in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
    Garcia del Muro, Xavier
    Maurel, Joan
    Martinez Trufero, Javier
    Lavernia, Javier
    Lopez-Pousa, Antonio
    De Las Penas, Ramon
    Cubedo, Ricardo
    Fra, Joaquin
    Casado, Antonio
    De Juan, Ana
    Jimenez Colomo, Laura
    Martin Broto, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
    Xavier García del Muro
    Joan Maurel
    Javier Martínez Trufero
    Javier Lavernia
    Antonio López Pousa
    Ramón de las Peñas
    Ricardo Cubedo
    José Pablo Berros
    Antonio Casado Herráez
    Ana de Juan
    Javier Martín Broto
    Investigational New Drugs, 2018, 36 : 468 - 475
  • [43] Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
    Garcia del Muro, Xavier
    Maurel, Joan
    Martinez Trufero, Javier
    Lavernia, Javier
    Lopez Pousa, Antonio
    de las Penas, Ramn
    Cubedo, Ricardo
    Pablo Berros, Jose
    Casado Herraez, Antonio
    de Juan, Ana
    Martin Broto, Javier
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (03) : 468 - 475
  • [44] CHEMOTHERAPY IN THE MULTIDISCIPLINARY APPROACH TO SOFT-TISSUE SARCOMAS - EORTC SOFT-TISSUE AND BONE SARCOMA GROUP STUDIES IN PERSPECTIVE
    VERWEIJ, J
    VANOOSTEROM, AT
    SOMERS, R
    SANTORO, A
    ROUESSE, J
    KEIZER, J
    TURSZ, T
    WOLL, P
    STEWARD, W
    BUESA, J
    KERBRAT, P
    WAGENER, D
    BRAMWELL, V
    THOMAS, D
    VANGLABBEKE, M
    MOURIDSEN, HT
    ANNALS OF ONCOLOGY, 1992, 3 : S75 - S80
  • [45] TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS WITH LOW-DOSE METHOTREXATE - A PHASE-II TRIAL BY THE EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER (EORTC) SOFT-TISSUE AND BONE SARCOMA GROUP
    BUESA, JM
    MOURIDSEN, HT
    SANTORO, A
    SOMERS, R
    BRAMWELL, V
    VANOOSTEROM, AT
    WAGENER, T
    VENDRIK, C
    THOMAS, D
    CANCER TREATMENT REPORTS, 1984, 68 (04): : 683 - 684
  • [46] HIGH-DOSE IFOSFAMIDE BY INFUSION WITH MESNA IN ADVANCED SOFT-TISSUE SARCOMA
    STUARTHARRIS, R
    HARPER, PG
    KAYE, SB
    WILTSHAW, E
    CANCER TREATMENT REVIEWS, 1983, 10 : 163 - 164
  • [47] Phase II study of neoadjuvant dose-intensive chemotherapy with adriamycin and ifosfamide followed by high-dose ICE in locally advanced soft tissue sarcomas
    Hartmann, Joerg T.
    Oechsle, Karin
    Brugger, Wolfram
    Mergenthaler, Hans-Guenther
    Aebert, Hermann
    Teichmann, Reinhard
    Rudert, Maximilian
    De Zwart, Peter M.
    Budach, Wilfried
    Kanz, Lothar
    ANNALS OF ONCOLOGY, 2004, 15 : 198 - 199
  • [48] Liposomal Doxorubicin (Caelyx) in advanced pretreated Soft Tissue Sarcomas: A phase II study of the Italian Sarcoma Group (ISG)
    Toma, S
    Tucci, A
    Villani, G
    Carteni, G
    Spadini, N
    Palumbo, R
    ANTICANCER RESEARCH, 2000, 20 (1B) : 485 - 491
  • [49] Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas
    Maurel, Joan
    Lopez-Pousa, Antonio
    de las Penas, Ramon
    Fra, Joaquin
    Martin, Javier
    Cruz, Josefina
    Casado, Antonio
    Poveda, Andres
    Martinez-Trufero, Javier
    Balana, Carmen
    Auxiliadora Gomez, Maria
    Cubedo, Ricardo
    Gallego, Oscar
    Rubio-Viqueira, Belen
    Rubio, Jordi
    Andres, Raquel
    Sevilla, Isabel
    Jose de la Cruz, Juan
    Garcia del Muro, Xavier
    Maria Buesa, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1893 - 1898